Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | DHODH | Q02127 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10987362 | 0.84 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNA7DHODHGBA1 | |
| SCHEMBL2392177 | 0.80 | CYP3A4 (0.47) | ALDH1A1LMNANR1H2NR1H3 | |
| SCHEMBL6606938 | 0.79 | NR1H2 (0.54) | ALDH1A1KDM4ENR1H2NR1H3 | |
| SCHEMBL6716687 | 0.78 | CRHBP (0.61) | CHRNB2CHRNA4DHODHALDH1A1LMNA | |
| SCHEMBL7789996 | 0.76 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA7DHODHGBA1 | |
| SCHEMBL12888668 | 0.76 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA7GBA1ALDH1A1 | |
| SCHEMBL30632262 | 0.75 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL3460939 | 0.75 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL10028665 | 0.75 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL3633941 | 0.75 | GRM2 (0.53) | CHRNB2CHRNA4DHODHGBA1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| EP-1418906-A1 | AMINOALKYL-SUBSTITUTED AROMATIC BICYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2004-05-19 | — | — | EP | disclosed |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | US | disclosed |
| WO-2003015769-A1 | AMINOALKYL-SUBSTITUTED AROMATIC BICYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | CHRNB2 741/4885CHRNA4 553/4885CHRNA7 428/4885 |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | CHRNB2 741/4885CHRNA4 553/4885CHRNA7 428/4885 |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | CHRNB2 741/4885CHRNA4 553/4885CHRNA7 428/4885 |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | CHRNB2 741/4885CHRNA4 553/4885CHRNA7 428/4885 |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | CHRNB2 741/4885CHRNA4 553/4885CHRNA7 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.